 Home > Biochemistry News > Biotechnology News > Gene therapy phase 3 clinical results achieved key results, 67% of patients' skin wounds healed completely

Gene therapy phase 3 clinical results achieved key results, 67% of patients' skin wounds healed completely

 Last Update: 2022-01-12
 Source: Internet
 Author: User

Tags

1 6 symbol

molecular bio products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 29, 2021, Krystal Biotech announced that a pivotal phase 3 clinical trial of Vyjuvek (beremagene geperpavec, B-VEC), a topical topical gene therapy under investigation, has achieved positive top-line results

DEB is a rare and serious single-gene chronic genetic disease.

Different from the current standard treatment, Vyjuvek aims to treat DEB at the molecular level by providing a template for the production of normal COL7 protein in the skin cells of patients

▲ Mechanism of action of Vyjuvek (picture source: Krystal Biotech official website)

31 DEB patients were enrolled in this phase 3 clinical trial.

At 6 months of treatment, compared with placebo (22%), 67% of patients in the Vyjuvek group had wounds healed completely (p<0.

At 3 months of treatment, compared with placebo (20%), 71% of patients in the Vyjuvek group had their wounds healed completely (p<0.

Vyjuvek is well tolerated, and no serious adverse events related to the drug have been reported or the drug has been discontinued due to treatment

▲Efficacy results of Vyjuvek's Phase 3 clinical trial (picture source: Krystal official website)

Reference materials:

[1] Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.